PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer

• Published in: Clinical cancer research Vol. 20; no. 22; pp. 5823 - 5834
• Main Authors: Markou, Athina, Farkona, Sofia, Schiza, Christina, Efstathiou, Tonia, Kounelis, Sophia, Malamos, Nikos, Georgoulias, Vassilis, Lianidou, Evi
• Format: Journal Article
• Language: English
• Published: United States 15.11.2014
• Subjects: Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Case-Control Studies; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Disease Progression; DNA Mutational Analysis - methods; Exons; Female; Humans; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating - metabolism; Phosphatidylinositol 3-Kinases - genetics; Prognosis; Sensitivity and Specificity

Molecular characterization of circulating tumor cells (CTC) is crucial for the investigation of molecular-targeted therapies while PIK3CA somatic mutations play a crucial role in therapy response. We investigated the presence of PIK3CA mutations in CTC and whether this is associated with clinical ou...